Quantum Biopharma (QNTM) Non Operating Interest Expenses (2019 - 2026)
Quantum Biopharma's (QNTM) quarterly Non Operating Interest Expenses came in at $84532.0 in Q2 2026, down 27.73% year-over-year from $116962.0 in Q2 2025, and up 269.88% quarter-over-quarter from $22854.0 in Q1 2026.
Powered by 
Analysis
Quantum Biopharma (QNTM) Non Operating Interest Expenses (2019 - 2026) Analysis & Trends
Quantum Biopharma has disclosed Non Operating Interest Expenses across 8 years of filings, most recently posting $84532.0 for Q2 2026.
- In Q2 2026, Non Operating Interest Expenses fell 27.73% year-over-year to $84532.0; the TTM figure through Jun 2026 stood at $126319.0 (down 16.55% YoY), while the FY2025 annual figure was $158063.0, up 378.73% from the prior year.
- Non Operating Interest Expenses came in at $84532.0 for Q2 2026 at Quantum Biopharma, up from $22854.0 in the prior quarter.
- In the past five years, Non Operating Interest Expenses ranged from a high of $116962.0 in Q2 2025 to a low of -$72637.0 in Q4 2025.
- Average Non Operating Interest Expenses over 5 years is $20446.3, with a median of $12414.0 recorded in 2024.
- Year-over-year, Non Operating Interest Expenses jumped 15525.0% in 2024 and plunged 3973.97% in 2025.
- Over 5 years, Non Operating Interest Expenses stood at $135.0 in 2022, then tumbled by 91.11% to $12.0 in 2023, then jumped by 15525.0% to $1875.0 in 2024, then sank by 3973.97% to -$72637.0 in 2025, then surged by 216.38% to $84532.0 in 2026.
- Per Business Quant data, the three most recent Non Operating Interest Expenses figures were $84532.0 in Q2 2026, $22854.0 in Q1 2026, and -$72637.0 in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Interest Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn | 673.00 Mn |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn | 247.00 Mn |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn | 11.00 Mn |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn | -1.00 Mn |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn | 82.05 Mn |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn | - |
| 10 | Quantum Biopharma | 11.80 Mn | 8.15 Mn | - | 84,532.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 84,532.00 |
| Mar 31, 2026 | 22,854.00 |
| Dec 31, 2025 | -72,637.00 |
| Sep 30, 2025 | 91,570.00 |
| Jun 30, 2025 | 116,962.00 |
| Mar 31, 2025 | 22,168.00 |
| Dec 31, 2024 | 1,875.00 |
| Sep 30, 2024 | 10,371.00 |
| Jun 30, 2024 | 8,357.00 |
| Mar 31, 2024 | 12,414.00 |
| Dec 31, 2023 | 12.00 |
| Sep 30, 2023 | -380.00 |
| Mar 31, 2023 | 667.00 |
| Dec 31, 2022 | 135.00 |
| Sep 30, 2022 | 16,052.00 |
| Jun 30, 2022 | 16,253.00 |
| Mar 31, 2022 | 16,382.00 |
| Dec 31, 2021 | -50,232.00 |
| Sep 30, 2021 | 1,957.00 |
| Jun 30, 2021 | 18,917.00 |